These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38247096)

  • 21. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis.
    Shimura M; Mizuma M; Hayashi H; Mori A; Tachibana T; Hata T; Iseki M; Takadate T; Ariake K; Maeda S; Ohtsuka H; Sakata N; Morikawa T; Nakagawa K; Naitoh T; Kamei T; Motoi F; Unno M
    Surg Case Rep; 2017 Dec; 3(1):132. PubMed ID: 29285651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
    Latenstein AEJ; Mackay TM; Creemers GJ; van Eijck CHJ; de Groot JWB; Haj Mohammad N; Homs MYV; van Laarhoven HWM; Molenaar IQ; Ten Tije BJ; de Vos-Geelen J; Besselink MG; van der Geest LGM; Wilmink JW;
    Acta Oncol; 2020 Jun; 59(6):705-712. PubMed ID: 32056483
    [No Abstract]   [Full Text] [Related]  

  • 24. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-Term Survival Following Multidisciplinary Therapy for Pancreatic Head Cancer with Liver Metastasis].
    Kiyota S; Tanimura T; Koda M; Kurashima Y; Hashiba R; Morita R; Katsuragi K; Ishigami K
    Gan To Kagaku Ryoho; 2020 Sep; 47(9):1375-1377. PubMed ID: 33130704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
    Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
    Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
    Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy].
    Kurahara H; Shinchi H; Maemura K; Mataki Y; Sakoda M; Iino S; Ueno S; Hiraki Y; Takao S; Natsugoe S
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):481-3. PubMed ID: 22421785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
    Ottaiano A; Capozzi M; DE Divitiis C; VON Arx C; DI Girolamo E; Nasti G; Cavalcanti E; Tatangelo F; Romano G; Avallone A; Tafuto S
    Anticancer Res; 2017 Apr; 37(4):1975-1978. PubMed ID: 28373469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Curative Resection of Pancreatic Head Cancer with Liver Metastasis after GEM plus Nab-PTX Therapy].
    Yotsumoto H; Yamamoto N; Kamiya M; Inoue H; Murakawa M; Aoyama T; Numata M; Hayashi T; Yamada T; Ohshima T; Shiozawa M; Rino Y; Masuda M; Morinaga S
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):169-171. PubMed ID: 30765677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report.
    Tsutsumi C; Abe T; Shinkawa T; Nishihara K; Tamiya S; Nakano T
    Surg Case Rep; 2020 Jul; 6(1):157. PubMed ID: 32621095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
    Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
    J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experience with Gemcitabine plus Nab-Paclitaxel Therapy for Advanced Metastatic Pancreatic Cancer in Our Hospital].
    Hagino S; Nakayama A; Sakamoto K
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1671-1673. PubMed ID: 28133094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
    Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
    Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
    Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
    Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy].
    Sato Y; Tsuchiya Y; Aizawa M; Nomura T; Nashimoto A
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1151-4. PubMed ID: 25248901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report.
    Yokoyama T; Makino H; Hirakata A; Ueda J; Takata H; Okusa M; Kawashima M; Tsujino T; Hosone M; Matsushita A; Nakamura Y; Yoshida H
    J Nippon Med Sch; 2019 Dec; 86(5):284-290. PubMed ID: 31105119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
    Tokairin Y; Iida M; Yamazaki S
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2123-5. PubMed ID: 19106544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.